Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade)

Group 1 - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck from 2009 to 2013 and has experience in biotech startups including Theravance and Aspira [1] - Brendan is a co-founder of 1200 Pharma, which spun out of Caltech and received significant investment in the 8 figures [1] Group 2 - The company has a beneficial long position in the shares of CORT, indicating a positive outlook on the stock [2] - The author expresses personal opinions and is not receiving compensation from any mentioned companies [2] Group 3 - Seeking Alpha emphasizes that past performance does not guarantee future results and does not provide specific investment recommendations [3]